First Time Loading...

Janux Therapeutics Inc
NASDAQ:JANX

Watchlist Manager
Janux Therapeutics Inc Logo
Janux Therapeutics Inc
NASDAQ:JANX
Watchlist
Price: 47.99 USD 1.89% Market Closed
Updated: May 21, 2024

Janux Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Janux Therapeutics Inc
Net Income (Common) Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Janux Therapeutics Inc
NASDAQ:JANX
Net Income (Common)
-$58.3m
CAGR 3-Years
-105%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$6B
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$484m
CAGR 3-Years
17%
CAGR 5-Years
-39%
CAGR 10-Years
-20%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$4B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Janux Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-58.3m USD

Based on the financial report for Dec 31, 2023, Janux Therapeutics Inc's Net Income (Common) amounts to -58.3m USD.

What is Janux Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-105%

Over the last year, the Net Income (Common) growth was 8%. The average annual Net Income (Common) growth rates for Janux Therapeutics Inc have been -105% over the past three years .